This website is intended for use by residents of Sweden only
About Isofol
Isofol Medical AB (publ) is developing the drug candidate arfolitixorin with the aim of increasing the efficacy of current standard treatments for colorectal cancer and certain other tumor diseases. A Phase III study of arfolitixorin has been completed and the company is now evaluating opportunities to advance the drug candidate toward a marketing authorization application by conducting additional studies and entering potential partnerships. Isofol Medical AB (publ) is traded on Nasdaq Stockholm.
Upcoming Events
- May 08, 2024 - May 08, 2024
Interim report January-March 2024 - August 21, 2024 - August 21, 2024
Interim report January-June 2024 - November 12, 2024 - November 12, 2024
Interim report June-September 2024
Media – Lates pressreleases
Isofol’s Japanese partner Solasia intensifies its commitment to the clinical development of arfolitixorin
GOTHENBURG, Sweden, March 19, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), (”Isofol”), today announces that the company’s collaboration partner, the Japanese pharmaceutical…
Isofol presents a clinical development plan for arfolitixorin
GOTHENBURG, Sweden, March 19, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), (”Isofol”), today presents the company’s continued strategy and clinical development program…
Isofol invites to investor meeting on March 19
GOTHENBURG, Sweden, March 1, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), hereby invites investors and shareholders to an investor meeting to present…
INVESTORS – latest reports and presentations
FOLLOW US
Stay updated on the latest news by
following Isofol on Linkedin.